Literature DB >> 30528604

Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.

Bei Cheng1, Feng Gao1, Erica Maissy1, Peisheng Xu2.   

Abstract

Suramin (SM), a drug for African sleeping sickness and river blindness therapy, has been investigated in various clinical trials for cancer therapy. However, SM was eventually withdrawn from the market because of its narrow therapeutic window and the side effects associated with multiple targets. In this work, we developed a simple but effective system based on a nontoxic dose of SM combined with a chemotherapeutic agent for the treatment of metastatic triple-negative breast cancer (TNBC). SM and glycol chitosan (GCS) formed nanogels because of the electrostatic effect, whereas doxorubicin (DOX) was incorporated into the system through the hydrophilic and hydrophobic interactions between DOX and GCS as well as the ionic interactions between DOX and SM to yield GCS-SM/DOX nanoparticles (NPs). GCS-SM/DOX NPs have a size of approximately 186 nm and a spherical morphology. In vitro experiments showed that GCS-SM NPs could effectively inhibit cancer cell migration and invasion, as well as angiogenesis. Furthermore, in a TNBC lung metastasis animal model, GCS-SM/DOX NPs significantly reduced tumor burden and extended the lifespan of animals, while not inducing cardio and renal toxicities associated with the DOX and SM, respectively. As all the components used in this system are biocompatible and easy for large-scale fabrication, the GCS-SM/DOX system is highly translatable for the metastatic breast cancer treatment. STATEMENT OF SIGNIFICANCE: The doxorubicin-loaded glycol chitosan-suramin nanoparticle (GCS-SM/DOX) is novel in the following aspects: SM acts as not only a gelator for the first time in the preparation of the nanoparticle but also an active pharmaceutical agent in the dosage form. GCS-SM/DOX NP significantly reduced tumor burden and extended the lifespan of animals with triple-negative breast cancer lung metastasis. GCS-SM/DOX NPs attenuate cardio and renal toxicities associated with the DOX and SM. The GCS-SM/DOX system is highly translatable because of its simple, one-pot, and easy-to-scale-up preparation protocol.
Copyright © 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiangiogenesis; Antimetastasis; Doxorubicin; Nanoparticle; Suramin; Triple-negative breast cancer

Mesh:

Substances:

Year:  2018        PMID: 30528604      PMCID: PMC6362832          DOI: 10.1016/j.actbio.2018.12.010

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  59 in total

1.  Cellular uptake of nanoparticles by membrane penetration: a study combining confocal microscopy with FTIR spectroelectrochemistry.

Authors:  Tiantian Wang; Jing Bai; Xiue Jiang; G Ulrich Nienhaus
Journal:  ACS Nano       Date:  2012-01-17       Impact factor: 15.881

Review 2.  Roles of fibroblast growth factor receptors in carcinogenesis.

Authors:  Ellen Margrethe Haugsten; Antoni Wiedlocha; Sjur Olsnes; Jørgen Wesche
Journal:  Mol Cancer Res       Date:  2010-10-13       Impact factor: 5.852

Review 3.  FGF receptor inhibitors: role in cancer therapy.

Authors:  Gennaro Daniele; Jesus Corral; L Rhoda Molife; Johann S de Bono
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 4.  Suramin: clinical uses and structure-activity relationships.

Authors:  Ross P McGeary; Andrew J Bennett; Quoc B Tran; Kelly L Cosgrove; Benjamin P Ross
Journal:  Mini Rev Med Chem       Date:  2008-11       Impact factor: 3.862

5.  Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers.

Authors:  Carrie E Kosarek; Xiao Hu; C Guillermo Couto; William C Kisseberth; Eric M Green; Jessie L S Au; M Guillaume Wientjes
Journal:  J Vet Intern Med       Date:  2006 Sep-Oct       Impact factor: 3.333

Review 6.  Fibroblast growth factor receptor inhibitors.

Authors:  Suneel B V S Kumar; Lakshmi Narasu; Rambabu Gundla; Raveendra Dayam; Sarma J A R P
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

7.  Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.

Authors:  S Song; M G Wientjes; Y Gan; J L Au
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

8.  Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice.

Authors:  E C Holland; H E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

9.  Mussel-inspired PLGA/polydopamine core-shell nanoparticle for light induced cancer thermochemotherapy.

Authors:  Huacheng He; Eleni Markoutsa; Yihong Zhan; Jiajia Zhang; Peisheng Xu
Journal:  Acta Biomater       Date:  2017-07-05       Impact factor: 8.947

10.  Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer.

Authors:  Darren C Tomlinson; Fiona R Lamont; Steve D Shnyder; Margaret A Knowles
Journal:  Cancer Res       Date:  2009-05-19       Impact factor: 12.701

View more
  7 in total

1.  The anti-parasitic agent suramin and several of its analogues are inhibitors of the DNA binding protein Mcm10.

Authors:  Carolyn N Paulson; Kristen John; Ryan M Baxley; Fredy Kurniawan; Kayo Orellana; Rawle Francis; Alexandra Sobeck; Brandt F Eichman; Walter J Chazin; Hideki Aihara; Gunda I Georg; Jon E Hawkinson; Anja-Katrin Bielinsky
Journal:  Open Biol       Date:  2019-08-14       Impact factor: 6.411

2.  Extracellular ATP Mediates Cancer Cell Migration and Invasion Through Increased Expression of Cyclooxygenase 2.

Authors:  Shilpa Sharma; Harshit Kalra; Ravi Shankar Akundi
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

3.  Molecular Targeting of VEGF with a Suramin Fragment-DOCA Conjugate by Mimicking the Action of Low Molecular Weight Heparins.

Authors:  Jooho Park; Tae-Bong Kang; Ji-Hong Lim; Hyung-Sik Won
Journal:  Biomolecules       Date:  2020-12-31

Review 4.  Polymeric Nanoparticles: Exploring the Current Drug Development and Therapeutic Insight of Breast Cancer Treatment and Recommendations.

Authors:  Ali Sartaj; Zufika Qamar; Farheen Fatima Qizilbash; Shadab Md; Nabil A Alhakamy; Sanjula Baboota; Javed Ali
Journal:  Polymers (Basel)       Date:  2021-12-15       Impact factor: 4.329

5.  Structure-based identification of a new IAP-targeting compound that induces cancer cell death inducing NF-κB pathway.

Authors:  Federica Cossu; Simone Camelliti; Daniele Lecis; Luca Sorrentino; Maria Teresa Majorini; Mario Milani; Eloise Mastrangelo
Journal:  Comput Struct Biotechnol J       Date:  2021-11-26       Impact factor: 7.271

Review 6.  Surface-functionalised hybrid nanoparticles for targeted treatment of cancer.

Authors:  Hasnat Tariq; Syed Ali Imran Bokhari
Journal:  IET Nanobiotechnol       Date:  2020-09       Impact factor: 1.847

7.  Aberrant MCM10 SUMOylation induces genomic instability mediated by a genetic variant associated with survival of esophageal squamous cell carcinoma.

Authors:  Jianbo Tian; Zequn Lu; Siyuan Niu; Shanshan Zhang; Pingting Ying; Lu Wang; Ming Zhang; Yimin Cai; Tianyi Dong; Ying Zhu; Rong Zhong; Zhihua Wang; Jiang Chang; Xiaoping Miao
Journal:  Clin Transl Med       Date:  2021-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.